Huntington’s Disease Treatment Market Adopts Innovation to Stay Competitive Forecast 2026

Huntington’s Disease Treatment Market Adopts Innovation to Stay Competitive Forecast 2026

Publication date: Jul 16, 2019

Growth of the Huntington’s disease treatment market is driven by rising prevalence of disease and increasing R&D programs by institutes and universities.

Organization such as CHID Foundation, Hereditary Disease Foundation, Huntington’s Disease Society of America, and International Huntington Association aid in creating awareness among patients and their family, which is also expected to support growth of the Huntington’s disease treatment market.

However, social stigma related to Huntington’s disease, stringent regulations related to drug approvals, and limited approved drug are factors expected to negatively affect growth of the Huntington’s disease treatment market.

Huntington’s disease treatment market is dominated by off-labeled drugs, which creates opportunity for key players, to develop new drugs.

Therefore, development of various new therapies for treatment of Huntington’s disease is expected to aid in growth of the market over the forecast period.

Valeant Pharmaceuticals International Inc. , Alnylam Pharmaceuticals Inc. , Ceregene Inc. , Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd. , Cortex Pharmaceuticals Inc. , Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer limited, Palobiofarma S. L, Omeros and Ipsen are the major players operating in Huntington’s disease treatment market.

Concepts Keywords
AIM Market trends technologies
Antidepressants Drug technology
Antipsychotic Disease
Antisense Drug Chorea
Autosomal Dominant Impulsiveness depression
Brain Disorder
Brain Imaging Huntingtons disease
Chorea Occupational therapy
Clinical Trials Psychotherapy
Cognitive Home remedies
Depression Speech therapy
Emerging Market Physical therapy
FDA Health
Genetic Disease Huntington’s disease
Genetic Test Life sciences
GlaxoSmithKline Articles
Heart Failure Therapeutic gene modulation
Huntingtin Biotechnology
Huntingtin Protein RTT
Huntington Lundbeck
Ipsen Teva Pharmaceutical Industries
Lundbeck Huntingtons
Movement Disorders Ionis Pharmaceuticals
Nerve Alnylam Pharmaceuticals
Neurogenesis Market trends technologies
Neurological Examination Transplantation
Neuron PDF
Neurons Drug technology
Neuropsychological Testing
Neurotropic
Occupational Therapy
Pfizer
Physical Therapy
Pneumonia
Prana
Progressive
Psychiatric Disorders
Psychiatric Evaluation
Psychotherapy
Siena
Social Stigma
SOM
Speech Therapy
Suicidal Tendencies
Symptomatic Treatment
Syndicated
Tetrabenazine
Teva Pharmaceutical Industries

Semantics

Type Source Name
gene UNIPROT CD5L
gene UNIPROT CD69
gene UNIPROT DNMT1
disease MESH movement disorders
disease MESH pneumonia
disease DOID pneumonia
disease MESH heart failure
disease MESH complications
disease MESH death
drug DRUGBANK Tetrabenazine
disease MESH lifestyle
disease MESH Growth
gene UNIPROT GRHL3
gene UNIPROT SLC6A4
gene UNIPROT HTT
gene UNIPROT PFDN1
gene UNIPROT PDF
gene UNIPROT GDF15
disease MESH suffering
disease MESH depression
drug DRUGBANK Pridopidine
drug DRUGBANK Laquinimod
drug DRUGBANK Deutetrabenazine
disease MESH social stigma
gene UNIPROT AICDA
disease MESH Hereditary Disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *